

# Clinical and laboratory comparison between End-Stage Kidney Disease patients with and without COVID-19: a cross-sectional study in a top referred hospital of West Nusa Tenggara



I Gede Yasa Asmara<sup>1\*</sup>, I Gusti Ngurah Ommy Agustriadi<sup>1</sup>, I Made Sujaya<sup>1</sup>,  
Salim Said Thalib<sup>2</sup>, Rina Lestari<sup>2</sup>, Suryani Padua Fatrullah<sup>2</sup>,  
Komang Sri Rahayu Widiarsari<sup>2</sup>, Indana Eva Ajmala<sup>2</sup>, Metta Octora<sup>3</sup>

## ABSTRACT

**Background:** The initial presentation of hospitalized End-Stage Kidney Disease (ESKD) patients with and without coronavirus disease 2019 (COVID-19) is similar and can overlap. We aimed to compare clinical and laboratory characteristics of the COVID-19 positive and negative patients to help clinicians screen and differentiate hospitalized ESKD patients.

**Methods:** We reviewed data from the medical record of ESKD patients hospitalized between May 1, 2020, and April 30, 2021. The study comprised all suspected COVID-19 patients. The COVID-19 positive was based on results from RT-PCR for SARS-CoV-2. The bivariate analysis was used to compare the positive and negative groups. The association of all characteristics and diagnosis of COVID-19 were then evaluated by multivariable analysis.

**Results:** There was twenty-nine percent of confirmed COVID-19 in 176 ESKD patients. The proportion of dyspnea, pulmonary edema, pleural effusion, and cardiomegaly were lower in the COVID-19 positive group. Diastolic blood pressure, pulse rate, white blood cell differential counts, and potassium were lower in the COVID-19 positive group. Using a multivariate analysis, eosinophil count  $<0.04 \times 10^3/\mu\text{l}$  ( $P<0.001$ , OR 3.50, 95%CI:0.123-0.665), monocyte count  $<0.69 \times 10^3/\mu\text{l}$  ( $P=0.004$ , OR 2.54, 95%CI:0.166-0.931), and neutrophil-to-lymphocyte ratio (NLR)  $<3.13$  ( $P=0.044$ , OR 3.18, 95%CI:0.102-0.968) were associated with the presence of COVID-19.

**Conclusions:** Leukocyte differential count and chest x-ray should be evaluated as an initial screening of COVID-19 in hospitalized ESKD. Low levels of monocyte and eosinophil count and mild elevation of NLR were associated with COVID-19 in ESKD patients.

**Keywords:** COVID-19, ESKD, eosinophil, monocyte, NLR.

**Cite This Article:** Asmara, I.G.Y., Agustriadi, I.G.N.O., Sujaya, I.M., Thalib, S.S., Lestari, R., Fatrullah, S.P., Widiarsari, K.S.R., Ajmala, I.E., Octora, M. 2022. Clinical and laboratory comparison between End-Stage Kidney Disease patients with and without COVID-19: a cross-sectional study in a top referred hospital of West Nusa Tenggara. *Bali Medical Journal* 11(3): 1074-1079. DOI: 10.15562/bmj.v11i3.3440

<sup>1</sup>Department of Internal Medicine, Faculty of Medicine, Universitas Mataram-West Nusa Tenggara General Hospital, Mataram, Indonesia;

<sup>2</sup>Department of Pulmonology, Faculty of Medicine, Universitas Mataram-West Nusa Tenggara General Hospital, Mataram, Indonesia;

<sup>3</sup>Department of Public Health, Faculty of Medicine, Universitas Mataram, Mataram, Indonesia;

\*Corresponding author:

I Gede Yasa Asmara;  
Department of Internal Medicine, Faculty of Medicine, Universitas Mataram-West Nusa Tenggara General Hospital, Mataram, Indonesia;  
[yasa.asmara@unram.ac.id](mailto:yasa.asmara@unram.ac.id)

Received: 2022-06-21

Accepted: 2022-08-02

Published: 2022-09-05

## INTRODUCTION

A new coronavirus, first discovered in China at the end of December 2019, can spread from person to person. The causative agent of Coronavirus Disease 2019 (COVID-19) is Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2).<sup>1</sup> COVID-19 can affect various organs such as the lungs, kidneys, heart, blood, and gastrointestinal tract.<sup>2</sup> End-Stage Kidney Disease (ESKD) patients are a potential target of SARS-CoV-2 infections because they have impaired immune systems and many comorbidities.<sup>3</sup> Most developing countries have variable access to health care. Most

hinterlands in this country do not have access to the diagnostic modality of COVID-19, such as Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) and chest computed tomography scan. They also do not have isolation hemodialysis (HD) treatment.

During the pandemic, every hospitalized patient, including ESKD, should be screened for COVID-19.<sup>4</sup> Several studies have reported the characteristics and outcomes of COVID-19 in ESKD or dialysis patients.<sup>3,5-9</sup> However, there is limited information on the differences between positive and negative COVID-19 in the ESKD population. A study showed

that the most common symptoms of COVID-19 in ESKD patients were fatigue and anorexia, just like uremic symptoms.<sup>9</sup> Uremic patients tend to exhibit less prominent or more significant variations in clinical symptoms of COVID-19.<sup>2</sup> ESKD patients might be missed in the process of differentiation and screening, so the diagnosis of COVID-19 in this population can be challenging. Identifying ESKD patients admitted to resource-limited hospitals is crucial because of solely uremic complications or COVID-19 infection. Patients with COVID-19 need more resources such as an isolation room, portable dialysis

machine, negative pressure room, dedicated staff, and personal protection equipment.<sup>10</sup> Therefore, we conducted this retrospective study of hospitalized ESKD patients in our hospital and compared the COVID-19 positive and negative groups. Risk factors associated with COVID-19 in ESKD patients were further explored. The result of this study might guide first-line clinicians in diagnosing COVID-19 in ESKD patients in resource-limited settings.

## METHODS

It is a cross-sectional analytic study. Data were extracted from patients' medical records in West Nusa Tenggara General Hospital (WNTGH) between May 1, 2020, and April 30, 2021. WNTGH is the top referral hospital in West Nusa Tenggara Province, located in Lombok Island, Indonesia. All ESKD patients with suspected COVID-19 were included in this study. Criteria of suspected COVID-19 were based on the COVID-19 management guidelines from the Indonesia Ministry of Health's 5<sup>th</sup> revision of 2020, including upper respiratory tract infection symptoms and history of contact with COVID-19 cases. Exclusion criteria included patients discharged against medical advice and patients with incomplete RT-PCR results. The diagnosis of COVID-19 is based on the WHO interim guidance and the Indonesian guideline of COVID-19 management.<sup>4,11</sup> The ESKD patients were divided into two groups based on the result of the RT-PCR test. Positive cases are defined as suspected COVID-19 with a single positive RT-PCR test. Negative cases are suspected COVID-19 with negative in two consecutive RT-PCR tests 24 hours apart. The data collected included demographics, history of contact, routine hemodialysis status, underlying ESKD, characteristics at presentation such as comorbidities, complications, symptoms, and signs, and laboratory and chest x-ray findings. The normal ranges of laboratory data were based on institutional standards. Three researchers collected medical record data. Discrepancies in the data were confirmed and discussed between the three researchers.

The analysis assessed differences in quantitative parameters between

COVID-19 and non-COVID-19 groups by the independent t-test or the Mann-Whitney U test. In contrast, differences in qualitative parameters in both groups were assessed by the X2 test, or Fisher's exact test, as appropriate. Table 1 shows the risk factors associated with COVID-19 as dichotomous independent variables. The correlation between the risk factors and diagnosis of COVID-19 was analyzed by Spearman's correlation and continued by logistic regression. All data analyses were performed by SPSS statistical software package (version 25.0; Chicago, IL), and a p-value < 0.05 was considered significant.

## RESULTS

During one year of the pandemic, 176 ESKD patients were hospitalized and suspected of COVID-19 after excluding six patients who refused the RT-PCR test and were discharged against medical advice. Fifty-one tested positive for COVID-19 based on RT-PCR, and ten of the confirmed patients died. So, the incidence of COVID-19 in our center was 29%, with a mortality rate of 19.6%. There were 51% males with a median age of 50 years. The most common etiology of ESKD was diabetic kidney disease. The three significant complications on admission were pulmonary edema (49%), hyponatremia (20%), and hyperkalemia (19%). Ninety of ESKD patients were already on maintenance HD, the median HD vintage was 11 months, and 59% had AV shunt access.

### Clinical comparison

There was no significant difference between the COVID-19 and negative groups in this study regarding demographics, history of routine HD, comorbidity, and underlying ESKD. There were significant differences between the COVID-19 positive and negative groups regarding admission signs, symptoms, and complications (Table 1). Patients with COVID-19 had a lower prevalence of dyspnea (21% vs. 79%,  $P=0.003$ ), a lower diastolic blood pressure (82 vs. 89 mmHg,  $P=0.025$ ), a lower pulse rate (88 vs. 100 x/minutes,  $P=0.003$ ), a higher temperature (36.7 vs. 36.5 °C,  $P=0.049$ ) than patients without COVID-19. Admission complication of pulmonary edema was less common

in ESKD patients with COVID-19 than without COVID-19 (19% vs. 81%,  $P=0.003$ ).

### Laboratory and chest X-ray comparison

Regarding laboratory parameters, ESKD patients with COVID-19 had lower white blood cell counts, neutrophil counts, monocyte counts, basophil counts, eosinophil counts, and potassium levels than patients without COVID-19 (Table 2). As for chest X-ray findings, ESKD patients with COVID-19 revealed less proportion of pulmonary edema (18% vs. 82%,  $P=0.007$ ), pleural effusion (17% vs. 83%,  $P=0.021$ ), and cardiomegaly (22% vs. 78%,  $P=0.017$ ). There was no significant difference in the proportion of ground-glass opacification, infiltration, or consolidation between the two groups (28% vs. 72%,  $P=0.422$ ).

### Uni- and Multivariable analyses of COVID-19 positive and negative groups

Based on the difference between the COVID-19 positive and negative groups (Table 1 and 2), we assessed symptoms of dyspnea, the complication of lung edema, white blood cell counts, monocyte counts, eosinophil counts, NLR, and chest X-ray findings such as pulmonary edema, pleural effusion and cardiomegaly by univariable analyses for the risk developing COVID-19. Less dyspnea, monocytopenia, low eosinophil count, and mild elevation of NLR were associated with COVID-19. We further analyzed using a multivariable logistic regression model for symptoms of dyspnea, monocyte group, eosinophil group, and NLR group. Among these factors, monocyte count  $<0.69 \times 10^3/\mu\text{l}$  ( $P=0.004$ , OR 2.54, 95%CI:0.166-0.931), eosinophil count  $<0.04 \times 10^3/\mu\text{l}$  ( $P<0.001$ , OR 3.50, 95%CI:0.123-0.665), and NLR  $<3.13$  ( $P=0.044$ , OR 3.18, 95%CI:0.102-0.968) were associated with the presence of COVID-19 (Table 3).

## DISCUSSION

Several studies reported different incidences of COVID-19 in HD patients, such as 2.2% in Wuhan,<sup>8</sup> 4.6% in Canada,<sup>12</sup> and 19.6% in the United Kingdom.<sup>13</sup> The prevalence of COVID-19 in our center was higher than in other studies since we included only symptomatic and suspected

patients who come to the hospital. Over 85% of HD patients have one or more comorbid conditions.<sup>3,8</sup> Like this study, Valeri et al. reported that almost all patients had hypertension, 69% diabetes, and 46% coronary artery disease.<sup>7</sup> The main complication at admission in this study was pulmonary edema. It might result from patient factors such as inadequate HD, non-compliance to routine HD schedule, or fear of contracting COVID-19 in the hospital.<sup>14</sup>

Our findings showed a statistically significant difference between the COVID-19 positive and negative groups in terms of diastolic blood pressure levels, pulse rate, and temperature levels. However, these results were relatively not

crucial in clinical settings. Despite the proportion of dyspnea being lower in the COVID-19 positive group, respiratory rates and oxygen saturation were similar between the two groups in this study. The main symptoms of COVID-19 were less common in the HD population than in non-HD patients,<sup>9</sup> which was in line with this study. In contrast, a study in India showed that 50% of confirmed COVID-19 in HD patients,<sup>5</sup> and 38% of HD patients in Romania complained of dyspnea.<sup>3</sup> Immune response in uremic conditions may alter the response to SARS-CoV-2 infection.<sup>2</sup> Hypoxia in COVID-19 may also be present in the infected ESKD population. Patients may not complain of shortness of breath despite hypoxia

requiring oxygen therapy.<sup>5</sup>

Based on multivariate analysis, our findings revealed that low eosinophil counts were associated with the diagnosis of COVID-19 in ESKD patients. Eosinophils are a subset of leukocytes that have long been associated with allergic diseases and parasitic infections. Recent studies have demonstrated the role of eosinophils in the immune response to viruses, particularly RNA viruses. Toll-like receptor 7 (TLR7), which functions to recognize RNA viruses, is abundant on the surface of eosinophil cells. Eosinophil counts have been associated with early markers of SARS-CoV-2 infection and the severity of COVID-19.<sup>15</sup> The eosinophil counts are an effective and efficient indicator in

**Table 1. Demographics and clinical characteristics of ESKD patients.**

| Characteristics                                   | Total (n=176)    | COVID-19 positive (n=51) | COVID-19 negative (n=125) | P value |
|---|------------------|--------------------------|---------------------------|---------|
| Age, year*  | 50 ± 13          | 53 ± 13                  | 49 ± 14                   | 0.053   |
| Men   | 89 (51)          | 23 (26)                  | 66 (74)                   | 0.354   |
| History of contact                                | 23 (13)          | 10 (44)                  | 13 (56)                   | 0.100   |
| Routine Hemodialysis                              | 90 (51)          | 25 (28)                  | 65 (72)                   | 0.720   |
| Comorbidity                                       | 156 (89)         | 45 (29)                  | 111 (71)                  | 0.915   |
| Diabetes  | 49 (28)          | 15 (31)                  | 34 (69)                   | 0.766   |
| Hypertension                                      | 125 (71)         | 37 (30)                  | 88 (70)                   | 0.776   |
| Cardiovascular disease                            | 47 (27)          | 9 (19)                   | 38 (81)                   | 0.083   |
| Others  | 36 (21)          | 7 (19)                   | 29 (81)                   | 0.157   |
| Admission symptoms                                |                  |                          |                           |         |
| Fever   | 33 (19)          | 13 (39)                  | 20 (61)                   | 0.143   |
| Cough   | 63 (36)          | 22 (35)                  | 41 (65)                   | 0.194   |
| Dyspnea   | 109 (62)         | 23 (21)                  | 86 (79)                   | 0.003   |
| Rhinorrhea  | 6 (3)            | 2 (33)                   | 4 (67)                    | 0.811   |
| Abdominal pain                                    | 28 (16)          | 8 (29)                   | 20 (71)                   | 0.959   |
| Myalgia   | 20 (11)          | 7 (35)                   | 13 (65)                   | 0.528   |
| Fatigue/malaise                                   | 97 (55)          | 28 (29)                  | 69 (71)                   | 0.971   |
| Nausea/vomiting                                   | 50 (28)          | 16 (32)                  | 34 (68)                   | 0.578   |
| Other symptoms                                    | 22 (13)          | 8 (36)                   | 14 (64)                   | 0.414   |
| Admission vital signs                             |                  |                          |                           |         |
| Systolic blood pressure, mmHg*                    | 157 ± 34         | 150 ± 33                 | 160 ± 35                  | 0.077   |
| Diastolic blood pressure, mmHg*                   | 87 ± 17          | 82 ± 15                  | 89 ± 17                   | 0.025   |
| Pulse rate, beats per minute <sup>†</sup>         | 98 (83-108)      | 88 (77-104)              | 100 (89-108)              | 0.003   |
| Respiration rate, breaths per minute <sup>†</sup> | 24 (20-28)       | 22 (20-26)               | 24 (20-28)                | 0.150   |
| Temperature, °C <sup>†</sup>                      | 36.6 (36.3-36.9) | 36.7 (36.5-37.0)         | 36.5 (36.3-36.8)          | 0.049   |
| Pulse oximetry, % <sup>†</sup>                    | 97 (94-98)       | 97 (95-98)               | 97 (94-98)                | 0.279   |
| Admission physical examination                    |                  |                          |                           |         |
| Conjunctival anemia                               | 139 (79)         | 38 (27)                  | 101 (73)                  | 0.353   |
| Crackles on auscultation                          | 91 (52)          | 23 (25)                  | 68 (75)                   | 0.263   |
| Ascites on percussion                             | 17 (10)          | 3 (18)                   | 14 (82)                   | 0.401   |
| Edema of lower extremities                        | 31 (18)          | 5 (16)                   | 26 (84)                   | 0.082   |

**Notes:** Data are given as n (%) or mean ± standard deviation\* or median (IQR)<sup>†</sup>.

P values comparing COVID-19 positive and COVID-19 negative are from the independent t-test\*, the Mann-Whitney U test<sup>†</sup>,  $\chi^2$ , or Fisher's exact test.

**Table 2. Laboratory findings of ESKD patients.**

| Laboratory findings   | Total (n=176)     | COVID-19 positive (n=51) | COVID-19 negative (n=125) | P value |
|---|-------------------|--------------------------|---------------------------|---------|
| White blood cells, 10 <sup>3</sup> µl                               | 10.5 (8.1-15.7)   | 9.5 (6.3-13.7)           | 11.0 (8.5-16.6)           | 0.015   |
| Hemoglobin, g/dl  | 8.0 (6.8-9.5)     | 8.7 (7.0-9.9)            | 7.8 (6.7-9.2)             | 0.058   |
| Thrombocyte, 10 <sup>3</sup> µl                                     | 213 (156-280)     | 200 (146-267)            | 230 (159-306)             | 0.109   |
| Neutrophil, 10 <sup>3</sup> µl                                      | 8.33 (5.48-13.64) | 6.99 (4.43-11.52)        | 8.86 (6.24-14.11)         | 0.017   |
| Lymphocyte, 10 <sup>3</sup> µl                                      | 1.05 (0.79-1.46)  | 1.12 (0.78-1.49)         | 1.02 (0.79-1.46)          | 0.557   |
| Monocyte, 10 <sup>3</sup> µl  | 0.69 (0.50-1.00)  | 0.57 (0.42-1.00)         | 0.73 (0.54-1.00)          | 0.021   |
| Basophil, 10 <sup>3</sup> µl  | 0.04 (0.02-0.06)  | 0.03 (0.01-0.05)         | 0.04 (0.02-0.06)          | 0.004   |
| Eosinophil, 10 <sup>3</sup> µl                                      | 0.12 (0.02-0.36)  | 0.08 (0.02-0.23)         | 0.15 (0.03-0.36)          | 0.047   |
| Neutrophil-Lymphocyte ratio   | 7.3 (4.5-15.2)    | 6.5 (3.0-13.6)           | 8.3 (5.1-15.6)            | 0.063   |
| estimated Glomerular Filtration Rate, ml/1.73m <sup>2</sup> /minute | 4.3 (2.7-6.7)     | 5.0 (3.5-8.5)            | 4.1 (2.6-6.1)             | 0.038   |
| Glucose, mg/dl  | 119 (100-158)     | 119 (90-158)             | 119 (103-157)             | 0.821   |
| Aspartate transaminase, U/L   | 27 (18-47)        | 27 (17-54)               | 27 (18-46)                | 0.951   |
| Alanine transaminase, U/L   | 24 (15-40)        | 24 (15-37)               | 24 (15-43)                | 0.565   |
| Sodium, mmol/L  | 134 (130-137)     | 132 (129-135)            | 135 (130-137)             | 0.062   |
| Potassium, mmol/L   | 5.1 (4.4-5.9)     | 4.6 (4.0-5.5)            | 5.2 (4.5-6.0)             | 0.008   |
| Chloride, mmol/L*   | 104 (100-108)     | 104 (98-107)             | 105 (101-109)             | 0.151   |
| C-reactive protein, mg/L†   | 41 (11-120)       | 53 (9-120)               | 37 (12-111)               | 0.236   |

**Notes:** Data were collected from 163 patients\* or from 160 patients†.

Data are given as median (IQR).

P values comparing COVID-19 positive and COVID-19 negative are from the Mann-Whitney U test.

**Table 3. Multivariable Analyses of Odds Ratio for mortality of COVID-19 in ESKD patients.**

| Variable   | Multivariable analysis |         |             |
|--|------------------------|---------|-------------|
|  | OR                     | P value | 95% CI      |
| Neutrophil-to-lymphocyte ratio <3.13             | 3.18                   | 0.044   | 0.102-0.968 |
| White blood cell count <10.0 x10 <sup>3</sup> µl | 1.08                   | 0.866   | 0.376-2.281 |
| Symptoms of dyspnea                              | 2.27                   | 0.048   | 0.195-0.994 |
| Chest X-ray pulmonary edema                      | 1.47                   | 0.404   | 0.274-1.685 |
| Chest X-ray pleural effusion                     | 1.38                   | 0.503   | 0.282-1.860 |
| Chest X-ray cardiomegaly                         | 1.63                   | 0.225   | 0.277-1.352 |
| Complications of lung edema                      | 1.41                   | 0.463   | 0.280-1.784 |
| Monocyte count <0.69 x10 <sup>3</sup> µl         | 2.54                   | 0.004   | 0.166-0.931 |
| Eosinophil count <0.04 x10 <sup>3</sup> µl       | 3.50                   | <0.001  | 0.123-0.665 |

**Notes:** OR - odds ratio; CI - confidence interval.

diagnosing COVID-19. A study reported that 71.7% of COVID-19 patients had low eosinophil counts, and the proportion was more remarkable than patients with pneumonia due to other causes.<sup>16</sup> Another study showed that eosinophils counts were lower in COVID-19 patients, then slowly increased to the average level in recovered patients. But, the number continued to decrease in deteriorated patients.<sup>17</sup>

Our study also revealed that monocytopenia and mild elevated NLR were a good indication of COVID-19 in ESKD patients. Monocytes might play an essential role in the host's defense

against COVID-19. The severe COVID-19 patients exhibit higher levels of monocyte counts.<sup>18</sup> In contrast, our study showed that monocyte count <0.69 x10<sup>3</sup>µl indicated COVID-19 in ESKD patients. The expected value of NLR in a healthy population is 1.0-2.3. NLR is said to be low if the level is < 0.7 and high if the level is >3.00.<sup>19</sup> A study demonstrated the use of NLR with a cut-off value of 5.87 to support the diagnosis of COVID-19.<sup>20</sup> A meta-analysis study reported that higher NLR levels were found in advanced COVID-19 stages while lower NLR levels were found in early COVID-19 stages. NLR has good

accuracy for diagnosis and good predictive ability of death in COVID-19.<sup>21</sup>

Pulmonary edema was infrequent chest x-ray findings in the COVID-19 positive group in this study. Pulmonary edema in the population of HD patients was associated with readmission and rehospitalization. A cohort study in the United States reported that 23% of HD patients had repeated hospital admissions in the past month, and 44% were associated with pulmonary edema. Factors influencing pulmonary edema in HD patients are dialysis vintage <1 year, chronic obstructive pulmonary disease, dialysis non-compliance, and congestive heart failure.<sup>22</sup> On the contrary, SARS-CoV-2 infection might directly cause pulmonary edema through the increased effect of bradykinin on its receptors in the lung. It is known that Angiotensin-Converting Enzyme 2 (ACE-2) converts angiotensin II to angiotensin 1-7, which has a vasodilating effect by stimulating Nitric Oxide (NO) synthase. ACE-2 also hydrolyzes the active metabolite of bradykinin, namely des-Arg<sup>9</sup>-bradykinin. The bind between des-Arg<sup>9</sup>-bradykinin and the bradykinin type 1 receptor (BKB1) on pulmonary endothelial cells causes fluid extravasation and edema. Suppression of



ACE-2 by the SARS-CoV-2 virus increased the number of bradykinin metabolites, increasing BKB1 receptor activation and pulmonary edema.<sup>23</sup> Pulmonary edema was infrequent in other studies or even normal chest x-ray findings in 7-19% of cases.<sup>7,9</sup>

The proportion of pleural effusion and cardiomegaly was lower in the COVID-19 positive group in this study. The feature of pleural effusion might rule out COVID-19 in hospitalized ESKD patients. The prevalence of pleural effusion in COVID-19 patients was only 9.55%. Pleural effusion was associated with an increased risk of disease severity and death in COVID-19.<sup>24</sup> The prevalence of cardiomegaly in regular HD patients in Mali is 55.68%. This feature was associated with hypertension-related kidney disease and left ventricular hypertrophy.<sup>25</sup> Cardiomegaly in patients without other comorbidities can be a feature of COVID-19 due to pericardial effusion or myocarditis.<sup>26</sup>

This study had some limitations—first, a limited number of cases from one single center. Second, not all patients documented CRP levels since this retrospective study. Third, the dynamics of clinical and laboratory changes during hospitalization were not analyzed, so the data on admission may differ from each stage of the disease. However, it is the first study of COVID-19 in this country's population with kidney disease. It also provides clinical features of COVID-19 at the first visit in hospitalized ESKD patients that may be useful in the screening and differentiation.

## CONCLUSIONS

ESKD patients with COVID-19 were less dyspnea and showed less frequent chest x-ray patterns of pulmonary edema, pleural effusion, and cardiomegaly. The COVID-19-positive patients presented with lower leukocyte, eosinophil, monocyte, and NLR. Eosinophil count  $<0.04 \times 10^3/\mu\text{l}$ , monocyte count  $<0.69 \times 10^3/\mu\text{l}$ , and NLR  $<3.13$  indicated that COVID-19 can help clinicians screen and differentiate hospitalized ESKD patients in resource-limited settings. Further studies are needed to determine the

dynamics of COVID-19 in ESKD during hospitalization.

## AUTHOR CONTRIBUTION

All authors contributed by preparing the proposal, data collection, data analysis, writing and revising the manuscript, and approving the final version for publication.

## FUNDING

None of funding.

## CONFLICT OF INTEREST

All authors declare no conflicts of interest.

## ETHICAL STATEMENT

The West Nusa Tenggara General Hospital Ethics Committee approved this research with ethical clearance reference number 070.1/21/KEP/2020.

## ACKNOWLEDGMENTS

The authors would like to thank all the doctors, nurses, and health care workers from the dialysis unit, isolation, and emergency room of West Nusa Tenggara General Hospital for their dedicated care for ESKD patients with COVID-19. We would also like to thank The Dean of Faculty of Medicine, Universitas Mataram, and The Director of West Nusa Tenggara General Hospital, Lombok, Indonesia, for their permission and support.

## REFERENCES

- Farouk SS, Fiaccadori E, Cravedi P, Campbell KN. COVID-19 and the kidney: what we think we know so far and what we don't. *Journal of Nephrol.* 2020;33(6):1213-8. <https://doi.org/10.1007/s40620-020-00789-y>
- Naicker S, Yang CW, Hwang SJ, Liu BC, Chen JH, Jha V. The Novel Coronavirus 2019 epidemic and kidneys. *Kidney Int.* 2020;97(5):824-8. <https://doi.org/10.1016/j.kint.2020.03.001>
- Stefan G, Mehedinti AM, Andreiana I, Zugravu AD, Cinca S, Busuioc R, et al. Clinical features and outcome of maintenance hemodialysis patients with COVID-19 from a tertiary nephrology care center in Romania. *Ren Fail.* 2021;43(1):49-57. <https://doi.org/10.1080/0886022X.2020.1853571>
- Kesehatan K. Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19) Revisi ke-5. Kementerian Kesehatan. 2020. Accessed on: 22 August 2021. Available at: [https://covid19.go.id/storage/app/media/Protokol/2020/Juli/REV-05\\_Pedoman\\_P2\\_COVID-19\\_13\\_Juli\\_2020.pdf](https://covid19.go.id/storage/app/media/Protokol/2020/Juli/REV-05_Pedoman_P2_COVID-19_13_Juli_2020.pdf)


- Sinha S, Swami R, Shakir A, Ali S, Bansode J, Mehta K. Clinical Profile and Outcome of Hemodialysis Patients with SARS COV2 Infection in a Tertiary Care Centre in Mumbai, India. *Indian Journal of Nephrology.* 2021;31(5):442-8. [https://doi.org/10.4103/ijn.IJN\\_377\\_20](https://doi.org/10.4103/ijn.IJN_377_20)
- Trujillo H, Caravaca-Fontán F, Sevillano Á, Gutiérrez E, Caro J, Gutiérrez E, et al. SARS-CoV-2 Infection in Hospitalized Patients With Kidney Disease. *Kidney Int Rep.* 2020;5(6):905-9. <https://doi.org/10.1016/j.ekir.2020.04.024>
- Valeri AM, Robbins-Juarez SY, Stevens JS, Ahn W, Rao MK, Radhakrishnan J, et al. Presentation and Outcomes of Patients with ESKD and COVID-19. *J Am Soc Nephrol.* 2020;31:1409-15. <https://doi.org/10.1681/asn.2020040470>
- Xiong F, Tang H, Liu L, Tu C, Tian JB, Lei CT, et al. Clinical Characteristics of and Medical Interventions for COVID-19 in Hemodialysis Patients in Wuhan, China. *J Am Soc Nephrol.* 2020;31(7):1387-98. <https://doi.org/10.1681/ASN.2020030354>
- Wu J, Li J, Zhu G, Zhang Y, Bi Z, Yu Y, et al. Clinical features of maintenance hemodialysis patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *Clin J Am Soc Nephrol.* 2020;15(8):1139-45. <https://doi.org/10.2215/CJN.04160320>
- PERNEFRI. Panduan Pencegahan Transmisi COVID-19 di Unit Dialisis. 2020. Accessed on: 12 December 2020. Available at: <https://pernefri.org/acara/webinar%20All.pdf>
- World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance January 28, 2020. Accessed on: December 12, 2020. Available at: <https://www.who.int/publications/i/item/10665-332299>
- Yau K, Muller MP, Lin M, Siddiqui N, Neskovic S, Shokar G, et al. COVID-19 Outbreak in an Urban Hemodialysis Unit. *Am J Kidney Dis.* 2020;76(5):690-5.e1. <https://doi.org/10.1053/j.ajkd.2020.07.001>
- Corbett RW, Blakey S, Nitsch D, Loucaidou M, McLean A, Duncan N, et al. Epidemiology of COVID-19 in an Urban Dialysis Center. *J Am Soc Nephrol.* 2020;31:1-9. <https://doi.org/10.1681/ASN.2020040534>
- Fisher M, Yunes M, Mokrzycki MH, Golestaneh L, Alahiri E, Coco M. Chronic Hemodialysis Patients Hospitalized with COVID-19: Short-term Outcomes in the Bronx, New York. *Kidney360.* 2020;1(8):755-62. <https://doi.org/10.34067/kid.0003672020>
- Huang R, Xie L, He J, Dong H, Liu T. Association between the peripheral blood eosinophil counts and covid-19 a meta-analysis. *Medicine (Baltimore).* 2021;100(23):e26047. <https://doi.org/10.1097/MD.00000000000026047>
- Xie G, Ding F, Han L, Yin D, Lu H, Zhang M. The role of peripheral blood eosinophil counts in COVID-19 patients. *Allergy.* 2021;76(2):471-82. <https://doi.org/10.1111/all.14465>
- Mu T, Yi Z, Wang M, Wang J, Zhang C, Chen H, et al. Expression of eosinophil in peripheral blood of patients with COVID-19 and its clinical significance. *J Clin Lab Anal.*

- 2021;35(1):e23620. <https://doi.org/10.1002/jcla.23620>
18. Rajamanickam A, Kumar NP, Pandiarajan AN, Selvaraj N, Munisankar S, Renji RM, et al. Dynamic alterations in monocyte numbers, subset frequencies and activation markers in acute and convalescent COVID-19 individuals. *Sci Rep.* 2021;11(1):20254. <https://doi.org/10.1038/s41598-021-99705-y>
  19. Zahorec R, Hulin I, Zahorec P. Rationale Use of Neutrophil-to-lymphocyte ratio for early diagnosis and stratification of COVID-19. *Bratisl Lek Listy.* 2020;121(7):466–70. <https://doi.org/10.4149/BLL>
  20. Song CY, Xu J, He JQ, Lu YQ. COVID-19 early warning score: A multi-parameter screening tool to identify highly suspected patients. *medRxiv.* 2020. <https://doi.org/10.1101/2020.03.05.20031906>
  21. Alkhatip AAAMM, Kamel MG, Hamza MK, Farag EM, Yassin HM, Elayashy M, et al. The diagnostic and prognostic role of neutrophil-to-lymphocyte ratio in COVID-19: a systematic review and meta-analysis. *Expert Rev Mol Diagn.* 2021;21(5):505–14. <https://doi.org/10.1080/14737159.2021.1915773>
  22. Plantinga LC, King LM, Masud T, Shafi T, Burkart JM, Lea JP, et al. Burden and correlates of readmissions related to pulmonary edema in US hemodialysis patients: A cohort study. *Nephrol Dial Transplant.* 2018;33(7):1215–23. <https://doi.org/10.1093/ndt/gfx335>
  23. Zwaveling S, Gerth van Wijk R, Karim F. Pulmonary edema in COVID-19: Explained by bradykinin? *J Allergy Clinical Immunol.* 2020;146(6):1454–5. <https://doi.org/10.1016/j.jaci.2020.08.038>
  24. Rathore SS, Hussain N, Manju AH, Wen Q, Tousif S, Avendaño-Capriles CA, et al. Prevalence and clinical outcomes of pleural effusion in COVID-19 patients: A systematic review and meta-analysis. *J Med Virol.* 2022;94(1):229–39. <https://doi.org/10.1002/jmv.27301>
  25. Sy S, Samaké M, Coulibaly M, Konaté M, Diallo D, Yattara H, et al. Prevalence of Cardiovascular Risk Factors in Chronic Hemodialysis Patients at the University Hospital Center of Point G in Bamako, Mali. *Open J Nephrol.* 2020;10(02):125–34. <https://doi.org/10.4236/ojneph.2020.102013>
  26. Mishra AK, Lal Aa, Sahu KK, Kranis M, Sargent J. Quantifying and reporting cardiac findings in imaging of COVID-19 patients. *Monaldi Arch Chest Dis.* 2020;90(4):627–32. <https://doi.org/10.4081/MONALDI.2020.1394>



This work is licensed under a Creative Commons Attribution

Keputusan Panitia Etik

|   |                                  |  |
|---|----------------------------------|--|
| <b>Komisi Etik Penelitian</b><br><b>RSUD Provinsi NTB</b>   | <b>Keputusan Penelaahan</b>      | <b>No : 070.1/ 21 /KEP/2020</b>  |
| <b>Karakteristik Dan Luaran Klinik COVID-19 Pada Pasien Penyakit Ginjal Kronis (PGK) Di RSUD Provinsi NTB, Lombok, Indonesia</b>  |                                  |  |
| <b>Peneliti :</b><br><b>dr. I Gede Yasa Asmara, M. Med. Sp. PD, FINASIM dkk</b>   |                                  |  |
| <b>Tanggal Penelitian :</b>   |                                  |  |
| <b>Kesimpulan :</b>   |                                  |  |
| <input checked="" type="checkbox"/> Disetujui   | <input type="checkbox"/> Ditolak | <input type="checkbox"/> Perlu Diperbaiki <input type="checkbox"/> Belum dapat dibahas |
| <b>Laik Etik</b>  |                                  |  |
| <b>Ketua Panitia Komisi Etik Penelitian</b><br><br><b>dr. Salim. S. Thalib, Sp.P</b><br><b>NIP. 19620106 198901 1 022</b> |                                  | <b>Tanggal, 18 Agustus 2020</b>  |

**Catatan :**

1. Peneliti wajib menyerahkan hasil penelitian selambat – lambatnya 1 (satu) bulan setelah selesai penelitian kepada Komisi Etik Penelitian Kesehatan RSUD Provinsi NTB. Apabila laporan penelitian tidak diserahkan, maka Komisi Etik berhak untuk membatalkan persetujuan yang diberikan.
2. Apabila pelaksanaan penelitian tidak sesuai dengan usulan kegiatan, Komisi Etik tidak bertanggung jawab terhadap Kelayakan Etik Penelitian tersebut.
3. Apabila ada perubahan prosedur/kegiatan penelitian, mohon agar mengusulkan kembali proposal Kelayakan Etik kepada Komisi Etik.